ArticleJournal of cellular and molecular medicine2025
Qianshi Mixture Treats Diabetic Nephropathy by Regulating Lipid Metabolism Reprogramming and Inhibiting Oxidative Stress Damage.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ferroptosis-related proteins ALOX15 and HMOX1 are upregulated and associated with inflammation in patients with diabetic nephropathy: a prospective cross-sectional study.International urology and nephrology · 2026Article
- Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy.Cellular and molecular life sciences : CMLS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Diabetic nephropathy (DN) is a major complication of diabetes that can advance to end-stage renal disease, posing a substantial health risk. The Qianshi Mixture (QSM) has shown therapeutic potential for DN; however, its pharmacological mechanisms remain insufficiently understood. We developed a DN model in mice and administered QSM as an intervention. To assess QSM's therapeutic effects, we measured the renal-function-related biochemical indicators and examined kidney pathological changes. We then applied transcriptomics and non-targeted metabolomics to explore QSM's impact on gene expression and metabolic products within DN mice renal tissues. Based on our multi-omics analysis, the effect of QSM on lipid-metabolism-related protein expression was confirmed by western blot in kidney tissue. Additionally, we evaluated the antioxidant and anti-apoptotic properties of QSM by measuring oxidative stress indicators. QSM intervention improved hyperglycemia and proteinuria in DN mice. It also reduced key markers of renal dysfunction whilst alleviating pathological changes in kidney tissue. Through transcriptomic and metabolomic analyses, we identified that QSM affected genes and metabolites involved in lipid metabolism pathways. Notably, differentially expressed genes included Ces2h, Ces1f and Alox5, whilst metabolites such as EPA, 9-Oxo-ODE and LPC (20:3) were altered. Further validation revealed that QSM increased the protein levels of CES2H and CES1F whilst decreasing the expression of FABP1, CD36, ALOX15 and ALOX5. Additionally, QSM reduced oxidative stress markers. QSM inhibited both oxidative stress and apoptosis in kidney tissues. QSM protects renal tissues in DN, likely through the regulation of lipid metabolism and the mitigation of oxidative stress damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.